Trevor Millar And Ibogaine Advocacy In Canada | Trevor Millar Ibogaine Record

A public role, carefully framed

Advocacy meets an urgent policy conversation.

The opioid crisis has made rapid-interruption claims compelling. It has also made rigorous safeguards more important.

Trevor Millar is a Canadian advocate working where ibogaine, addiction treatment, psychedelic medicine, and public policy meet. His work has drawn attention because Canada faces a toxic drug supply, escalating overdose prevention needs, and difficult questions about what responsible innovation should require.

Trevor Millar co-founded Liberty Root Therapy Ltd. in Vancouver to provide ibogaine treatment protocols for people struggling with severe substance use disorders. Public accounts of his work also connect Trevor Millar with Ambio Life Sciences’ leadership profile, an example of how advocacy, treatment ambitions, and research language can overlap.

That overlap needs precision. Ibogaine remains scientifically interesting, but advocacy does not establish efficacy. Canadian conversations should distinguish lived experience and early research from completed randomized evidence, especially for opioid use disorder, trauma, depression, anxiety, and other mental health concerns.

Millar served as Board Chair of MAPS Canada, where MAPS Canada promoted clinical research and public education. His record belongs to a broader psychedelic community in Canada rather than representing every view within it.

Natural botanical detail accompanying discussion of Tabernanthe iboga and ibogaine

Plant, molecule, context

What ibogaine is—and what it is not.

Ibogaine is an indole alkaloid derived primarily from the root bark of Tabernanthe iboga, a Central West African plant. Tabernanthe iboga is associated with the Bwiti tradition in Gabon, where an entheogen cannot be separated neatly from indigenous medicine, ceremony, community care, and cultural responsibility.

In contemporary settings, ibogaine is a psychoactive plant medicine discussed for addiction treatment and psychedelic-assisted therapy. The human liver metabolizes ibogaine into noribogaine, a related compound that interacts with multiple neuroreceptors. That pharmacology helps explain interest in therapeutic potential, but it does not make outcomes predictable for patients.

Advocates often describe reduced cravings and eased withdrawal symptoms within 24 to 72 hours. An intense psychospiritual state may last 12 to 36 hours, and some patients describe processing trauma or behavioral patterns during therapy. Those accounts matter, while still requiring careful research and honest informed consent.

Ibogaine and noribogaine are distinct compounds, even when they are discussed together.
Tabernanthe iboga carries cultural context that commercialization should not erase.
Psychedelic-assisted therapy is not a substitute for medical supervision, follow-up, or evidence.

Questions people bring to the topic

Legal status, safety, and evidence require separate answers.

Open each point for the distinction between regulatory status, potential benefit, and the safeguards that patient safety demands.

What is the regulatory status of ibogaine in Canada?

Health Canada added ibogaine to the federal Prescription Drug List in 2017, ending its earlier status as an unregulated natural health product. Ibogaine is not scheduled under the Controlled Drugs and Substances Act, a distinction from many classic psychedelics, but that does not mean it is approved for routine addiction treatment.

Health Canada physicians may apply through the Special Access Programme for emergency clinical interventions. The Special Access Programme is not a broad authorization pathway, and the prescription drug list should not be read as a general endorsement. A regulatory framework concerns access and oversight; it does not resolve efficacy or safety.

How is ibogaine discussed in opioid use disorder?

Ibogaine is promoted as a possible interruption of opioid withdrawal and dependency because noribogaine binds to several targets and some uncontrolled reports describe fewer cravings and withdrawal symptoms. Detoxification can be a powerful moment, but detoxification alone is not durable addiction treatment.

For opioid use disorder, research remains preliminary. Advocacy should not imply that a single treatment can replace continuing therapy, harm reduction, healthcare providers, stable housing, social support, or overdose prevention. The opioid crisis needs options, and it also needs evidence that withstands scrutiny.

What makes safety screening non-negotiable?

Ibogaine can carry life-threatening cardiac risks. Dose-dependent QT prolongation and ventricular arrhythmias, including torsades de pointes, are serious concerns. A baseline 12-lead electrocardiogram, or ECG, serum electrolyte testing, liver enzyme evaluation, medication review, and careful eligibility assessment are central safety protocols.

During the active treatment window, continuous cardiac telemetry, emergency capacity, and trained medical supervision are essential. Patient safety depends on the entire protocol: screening, doses, interaction risks, continuous observation, integration therapy, and follow-up. No public advocacy message should minimize this risk.

Evidence-first principle

Promise is not proof.

Research on ibogaine merits attention because the opioid crisis is devastating, not because urgency lowers the standard for safety or clinical trials.

“The responsible question is whether people can receive evidence-based care, meaningful consent, emergency readiness, and follow-up—not simply whether an intervention is natural or available.”
Trevor Millar Ibogaine Record · Independent information resource

Institutional leadership & community work

Liberty Root, MAPS Canada, and Roots to Thrive.

Trevor Millar’s advocacy in Vancouver is often discussed through Liberty Root, MAPS Canada, and British Columbia’s wider psychedelic community. Liberty Root was positioned around ibogaine treatment protocols for severe substance use disorders, while MAPS Canada emphasized public education and clinical research.

British Columbia has been a central jurisdiction for Canadian entheogenic therapy conversations and harm reduction experimentation. In a province shaped by the toxic drug supply, public health responses must hold both immediate survival and long-term healing in view.

Trevor Millar worked with healthcare leaders to co-create community-based integration care models and contributed to the Roots to Thrive program in British Columbia. Roots to Thrive is relevant because integration therapy asks what happens after an intense intervention, not only during it.

Community care can include therapy, peer support, practical stability, and healthcare providers who understand substance use without stigma. Harm reduction does not require choosing between overdose prevention and recovery-oriented goals; it asks providers and policy makers to reduce preventable death while supporting agency.

Accounts of Trevor Millar’s work appear across public interviews, including a discussion of ibogaine and the future of healing and an extended Behind the Shield conversation. These are useful records of advocacy, not substitutes for clinical trials.

For a broader institutional background, the Multidisciplinary Association for Psychedelic Studies describes its work around research and education. MAPS Canada’s Canadian role should likewise be understood within a contested field of policy, research, patient safety, and access.

A safety-centered pathway

Before, during, and after any high-risk intervention.

For people seeking understandable material about advocacy and risk, our evidence-oriented resource guides focus on questions to bring to qualified healthcare providers rather than treatment offers.

Information matters because ibogaine can interact with medications, medical histories, cardiac conditions, mental health vulnerabilities, and substance use patterns. An ECG is only one element of a full assessment.

01

Eligibility and cardiac screening

Safety protocols begin with medical history, medication review, baseline electrocardiogram testing, electrolyte and liver evaluations, and a careful review of QT prolongation risk.

02

Continuous medical supervision

During active dosing, patient safety requires monitored care, cardiac telemetry, emergency readiness, clear escalation procedures, and providers able to respond to arrhythmias.

03

Integration and continuing care

Integration therapy can address trauma, depression, anxiety, cravings, and practical recovery goals, while ongoing addiction treatment and harm reduction remain available.

The evidence gap

Why clinical trials and transparent policy matter.

Potential is still being tested

Ibogaine research has generated interest for opioid use disorder, trauma, and mental health, yet uncontrolled studies cannot settle questions of effectiveness, appropriate doses, selection criteria, or longer-term outcomes. Neuroplasticity is a research question, not a clinical guarantee.

Risk is not theoretical

Cardiac safety is central. QT prolongation, ECG changes, drug interactions, and ventricular arrhythmias mean that advocacy for access must include safety protocols, medical supervision, and candid discussion of serious adverse outcomes.

Policy needs precision

Canada can support carefully designed clinical trials while avoiding a regulatory framework that normalizes weak oversight. Health Canada review, public health priorities, and patient safety should guide a measured policy response.

Culture needs reciprocity

Commercial interest in Tabernanthe iboga should not detach the alkaloid from Gabon, indigenous medicine, or the Bwiti tradition. Ethical psychedelic medicine requires benefit-sharing, respect, and humility.

The Health Canada Special Access Programme information explains that access is evaluated within a restricted pathway rather than as general market approval. Regulatory discussions should remain distinct from claims about addiction treatment outcomes.

A useful baseline definition is available through Wikipedia’s overview of ibogaine, while clinical interpretation should prioritize primary research, qualified providers, and transparent safety reporting.

Harm reduction in context

Ibogaine is one question within a larger overdose response.

Advocates position ibogaine as an innovative intervention against fentanyl and contaminated illicit drug supplies in Western Canada. That framing reflects a real emergency: the opioid crisis has reshaped how people understand withdrawal symptoms, detoxification, relapse risk, and the need for overdose prevention.

But harm reduction is broader than a single intervention. It includes reducing exposure to a toxic drug supply, expanding non-stigmatizing healthcare, connecting patients to evidence-based addiction treatment, and making crisis response possible when people need it.

Canadian policy can make space for research without presenting ibogaine as a proven answer. Public health planning should consider patients who are interested in psychedelic medicine alongside those who prefer established therapy, medication options, peer support, or other forms of community care.

Discussion of Trevor Millar also appears in a Broken Brains episode on brain trauma and psychedelic therapy. Such interviews can clarify advocacy positions while leaving clinical claims to appropriate research methods.

For people tracking the subject over time, our chronology of Canadian advocacy developments places public statements and policy discussion alongside the evidence questions that remain unresolved.

About this resource

Independent information, without treatment promises.

Trevor Millar Ibogaine Record is a newly launched independent information company helping people understand Trevor Millar and ibogaine advocacy in Canada. Our approach to independence, clarity, and accuracy explains why this resource separates public advocacy from clinical evidence.

People navigating concussion-related questions can also find topic-specific context at ibogaine and concussion information, where the same caution about patient safety, research quality, and qualified medical guidance applies.

Explore evidence and risks

FAQ

Clear answers for a complicated Canadian conversation.

Who is Trevor Millar and what is his contribution to ibogaine advocacy?

Trevor Millar is a Canadian psychedelic-policy and ibogaine advocate. He co-founded Liberty Root Therapy Ltd. in Vancouver, served as Board Chair of MAPS Canada, and contributed to conversations about community-based integration care and the Roots to Thrive program in British Columbia.

His advocacy has helped keep ibogaine, addiction treatment, harm reduction, and policy reform visible in Canada. It should not be treated as proof that ibogaine is clinically established for opioid use disorder or other conditions.

How does ibogaine fit into harm reduction for the toxic drug crisis?

Some advocates see ibogaine as a possible tool for people facing opioid withdrawal, cravings, and a toxic drug supply. Harm reduction, however, is a broad public health practice: overdose prevention, safer access, non-stigmatizing care, treatment choice, and continuity of support all matter.

Ibogaine may be part of a policy and research conversation in Canada, but it should not displace established harm reduction services or create pressure on patients to pursue a high-risk intervention.

What ethical issues should be considered around ibogaine?

Ethical considerations include informed consent, transparent risk communication, access inequities, commercialization, ecological supply, and respect for Gabonese and Bwiti tradition. A plant medicine framework does not remove the need for rigorous safety, accountable providers, and ethical research.

A consumer-facing discussion of ibogaine supplements illustrates why people need clear distinctions between products, claims, and medically supervised contexts.

What should people verify before relying on an ibogaine claim?

Ask whether a claim comes from clinical trials, case reports, advocacy, a treatment center, or marketing. Check whether it addresses cardiac screening, electrocardiogram review, QT prolongation, medication interactions, doses, emergency protocols, medical supervision, integration therapy, and continuing care.

Public material includes a Canadian feature on ibogaine, PTSD, and addiction, a Globe and Mail opinion on PTSD treatment for veterans, and a New York Times magazine examination of ibogaine and trauma. Each should be read as context rather than personal medical advice.

Looking ahead

The future of psychedelic medicine in Canada depends on evidence and care.

Trevor Millar’s advocacy raises important questions about access, healing, and policy. The strongest answer is neither dismissal nor hype: it is stronger research, credible clinical trials, accountable safety protocols, cultural respect, and patient-centered public health.

Public records also include a Trevor Millar LinkedIn statement and a corporate appointment announcement. These materials document public-facing activity, while the central questions of evidence, safety, and regulation remain larger than any one biography.